Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2011 / Cilt: 21 - Sayı: 3

HL-60 akut promyelositik lösemi hücre kültürlerinde thalidomide ve rhGM-CSF kullanılmasının karbonhidrat metabo- lizmasına etkileri

Effects of thalidomide and rhGM-CSF on carbohydrate metabolism in HL-60 Acute promyelocytic leukemia cell line

Pages
170–175
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The study results indicated that the use of drugs for 2-days had no significant effect when compared with aerobic and anaerobic controls.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The purpose of this study is to investigate the in vitro effect of thalidomide and rhGM-CSF on energy metabolism rate in HL-60 cell lines.
📊
Key Findings & Data:HL-60 cells were incubated with radiolabelled glucose for 4 hours.
💡
Conclusion & Impact:The study results indicated that the use of drugs for 2-days had no significant effect when compared with aerobic and anaerobic controls.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The purpose of this study is to investigate the in vitro effect of thalidomide and rhGM-CSF on energy metabolism rate in HL-60 cell lines. HL-60 cells were incubated with radiolabelled glucose for 4 hours. Following incubation, radiolabelled CO2 was isolated and collected in specially designed scintillation vials. The other end-products of carbohydrate catabolism collected via anion-exchange chromatography were analyzed using liquid scintillation. Protein and glycogen levels for each group were also determined. The study results indicated that the use of drugs for 2-days had no significant effect when compared with aerobic and anaerobic controls. How- ever, groups treated with the drugs for 5 days showed significant differences. It was obvious that rhGM-CSF caused HL-60 leukemia cells to use aerobic glycolytic pathway for production of energy. When thalidomide and rhGM-CSF combination therapy results were compared with untreated control cells, it was observed that glycogen consumption was decreased by 50.37%, and CO2 produc- tion was increased by 94.03%. When compared with those of anaerobic controls, glycogen consumption and CO2 production rates were found to be decreased by 54.01% and increased by 96.59%, respectively. As a consequence, we found that those cell lines treated with combined use of Thalidomide and rhGM-CSF caused HL-60 leukemia cells to predominantly prefer aerobic glycolytic pathways for energy production.

Özet

Bu çalışma, HL-60 hücre kültürlerinde in vitro olarak thalidomide ve rhGM-CSF uygulamasının enerji metabolizmasına etkilerini araştırma amacı ile yapıldı. HL-60 hücre kültürleri radyoaktif glukozla 4 saat inkübe edildi. Ardından radioaktif işaretli CO2 özel sinti- lasyon viallerinde toplandı, karbonhidrat katabolizmasının diğer son ürünleri ise anyon değişim kromotografisi ile ayrıldı ve sıvı sinti- lasyon aracılığıyla analiz edildi. Ayrıca her grubun protein ve glikojen düzeyleri ölçüldü. ‹ki günlük ilaç kullanımı aerobik ve anaerobik kontrollerde anlamlı bir fark oluşturmazken beş günlük ilaç kullanımında anlamlı fark olduğu tespit edildi. rhGM-CSF uygulanan HL- 60 lösemi hücre kültürlerinin aerobik glikolitik yola kaydığı belirlendi. Thalidomide ve rhGM-CSF kombine tedavisinin sonuçları, ilaç verilmeyen aerobik kontrol grubuyla karşılaştırıldığında glikojen tüketiminin %50.37 azaldığı, CO2 üretiminin ise %94.03 oranında arttığı belirlendi. Kombine ilaç verilen grup anaerobik kontrolle karşılaştırıldığında ise, glikojen tüketiminin %54.01 azaldığı, CO2 üre- timin ise %96.59 arttığı belirlendi. Sonuç olarak Thalidomide ve rhGM-CSF kombine kullanıldığında, HL-60 lösemi hücrelerinin enerji üretiminde esas olarak aerobik glikolitik yolu tercih ettikleri belirlendi.

🔖

Cite This Article

BOYUNAĞA, H., DİKMEN, G., URAL, A. U., MELEKOĞLU, A. (2011). HL-60 akut promyelositik lösemi hücre kültürlerinde thalidomide ve rhGM-CSF kullanılmasının karbonhidrat metabo- lizmasına etkileri. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 21 - Sayı: 3, 170–175. https://ajindex.com/articles/322952

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Fischer CP, Bode BP, Souba WW. Adaptive alter ations in cellular metabolism with malignant transfor mation. Ann Surg 227: 627-34, 1998
  2. Semenza GL. Tumor metabolism: cancer cells give and take lactate. J Clin Invest 118: 3835-3837, 2008
  3. Newsholme EA, Board M. Application of metabolic control logic to fuel utilization and its significance in tumor cells. Adv Enzyme Regul 31: 225-246, 1991
  4. DeBerardinis RJ. Is cancer a disease of abnormal cel lular metabolism? New angles on an old idea. Genet Med 10: 767-777, 2008
  5. Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem. and Biophysic Res Comm 313: 459-465, 2004
  6. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7:11-20, 2008
  7. Tiffany N. Seagroves,1 Heather E et al Transcription Factor HIF-1 Is a Necessary Mediator of the Pasteur Effect in Mammalian Cells. Molecular and Cellular Biol ogy 21: 3436-3444, 2001
  8. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. Mar; 23: 537-548, 2009 9. Mayevsky A. Mitochondrial function and energy metabolism in cancer cells: Past overview and future perspectives. Mitochondrion 9: 165-179, 2009
  9. Mazurek S, Eigenbrodt E. The tumor metabolome. Anticancer Res 23: 1149-1154, 2003
  10. Melo RF, Stevan FR, Campello AP, et al. Occurrence of the Crabtree effect in HeLa cells. Cell Biochem Func 16: 99-105, 1998
  11. Hsu PP, Sabatini DM. Cancer cell metabolism: War burg and beyond. Cell 5;134: 703-707, 2008
  12. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324: 1029 33, 2009
  13. Holtz M, Forman SJ, Bhatia R. Growth factor stimula tion reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treat ment. Cancer Res 67: 1113-1120, 2007 15. Di Raimondo F, Palumbo GA, Molica S, et al. Angio genesis in chronic myeloproliferative diseases. Acta Haematol 106: 177-183, 2001
  14. Lowry OH, Rosbrough NJ, Farr A, et al. J Biol Chem 193: 265, 1951
  15. Hassid WZ, Abraham S. Chemical procedures for analysis of polysaccharides. Methods Enzymol 3-34, 1957
  16. Bentley R. The Enzymes. P. Boyer, H. Lardy, and K. Myrback, 2st edition. New York Academic Press, 1963: 567
  17. Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: Aerobic glycolysis in cancer associate